A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice is a dataset published in Cancers (2024). On theSindex it has a DataRank of 0.757, placing it in the top 26.6% of the data-sharing corpus. It has been cited 17 times, with 17 citing works in its 1-hop citation network. Its calibrated FAIR score is 6/100.
Ranks in the top 27% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
The headline score is computed from the scored criteria — the fact-shaped checks (a repository, an accession, a licence) that two independent models agree on. The advisory criteria below are real FAIR guidance but rest on judgment calls that models read differently, so they inform without moving the number.
“The data presented in this study are available on request from the corresponding author but limited to de-identified information approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations.”
No persistent identifier scheme string (DOI, Handle, ARK, URN, repository accession) is given for the dataset.
RDA-F1-01D — FAIR Data Maturity Model: 'Data is identified by a persistent identifier' (priorit · RDA-F1-02D — FAIR Data Maturity Model: 'Data is identified by a globally unique identifier' · FsF-F1-02D — F-UJI/FAIRsFAIR: 'Data is assigned a persistent identifier'
“The data presented in this study are available on request from the corresponding author but limited to de-identified information approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations.”
No repository name is given; the data are held by the authors, not a curated archive.
RDA-F4-01M — FAIR Data Maturity Model: metadata is offered so it can be harvested and indexed ( · NIH DMS Policy Element 4 (NOT-OD-21-014) — name the repository where data will be archived · NSTC Desirable Characteristics of Data Repositories (2022) — 'Long-Term Sustainability', 'Reten
No identifier or link for the dataset appears anywhere in the paper, either in the reference list or body text.
FORCE11 Joint Declaration of Data Citation Principles (2014) — data should be cited as a first- · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes · FsF-F3-01M — F-UJI: 'Metadata includes the identifier of the data it describes'
Advisory · not in the published score
“The data presented in this study are available on request from the corresponding author but limited to de-identified information approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations.”
The statement points to a person (corresponding author) rather than a repository record, matching Colavizza category 1.
Colavizza, Hrynaszkiewicz, Staden, Whitaker & McGillivray (2020), 'The citation advantage of li · Springer Nature research data policy — Data Availability Statements: standard statement templat · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes
“Patient demographic information, baseline clinical and histopathological characteristics, and next-generation sequencing data were collected.”
The dataset's content is described in a running prose sentence, not in an itemised inventory section or table. [majority verdict 'partial' (4/5 passes agreed)]
RDA-F2-01M — 'Rich metadata is provided to allow discovery' (priority Essential) · FsF-F2-01M — F-UJI: 'Metadata includes descriptive core elements to support data findability' · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data'
“The data presented in this study are available on request from the corresponding author but limited to de-identified information approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations.”
The only route is a discretionary request to a person, which is not a followable access route.
RDA-A1.1-01D — 'Data is accessible through a free access protocol' · FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · NSTC Desirable Characteristics of Data Repositories (2022) — 'Free and Easy Access'
Advisory · not in the published score
“The data presented in this study are available on request from the corresponding author but limited to de-identified information approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations.”
The paper describes an access action (request from the corresponding author) but does not apply an explicit access-level label. [majority verdict 'partial' (4/5 passes agreed)]
FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · RDA-A1-01M — metadata contains information to enable the user to get access to the data · COAR Controlled Vocabularies — Access Rights v1.0 (open / embargoed / restricted / metadata-onl
“The data presented in this study are available on request from the corresponding author but limited to de-identified information approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations.”
The gatekeeper is the corresponding author (a natural person), not an institutional committee or repository. [majority verdict 'partial' (3/5 passes agreed)]
NIH Genomic Data Sharing Policy (NOT-OD-14-124) — controlled-access via a Data Access Committee · RDA-A1.2-01D — 'Data is accessible through an access protocol that supports authentication and · NIH DMS Policy Element 5 (NOT-OD-21-014) — Access, Distribution, or Reuse Considerations (conse
No sentence in the paper states when the data become available or how long they persist.
NIH DMS Plan Element 4 (NOT-OD-21-014) — Data Preservation, Access, and Associated Timelines · NSTC Desirable Characteristics (2022), Organizational Infrastructure: 'Retention Policy' · RDA-A2-01M — 'Metadata is guaranteed to remain available after data is no longer available'
No file format token of any kind is named for the released data.
FsF-R1.3-02D — F-UJI: 'Data is available in a file format recommended by the target research co · RDA-R1.3-02D — data is expressed in a machine-understandable community standard · RDA-I1-01D — data uses a knowledge representation expressed in a standardised format
Advisory · not in the published score
No data or metadata community standard (e.g., MIAME, MINSEQE, BIDS) is named; only a clinical trial registration identifier is given.
RDA-R1.3-01M — 'Metadata complies with a community standard' (priority Essential) · RDA-R1.3-01D — 'Data complies with a community standard' · RDA-I2-01M — '(Meta)data use vocabularies that follow FAIR principles'
“based on the results of the randomized FLAURA trial (ClinicalTrials.gov number NCT02296125)”— not found in the paper; verdict downgraded
An identifier (ClinicalTrials.gov number) for an external resource (the FLAURA trial) is given in the text. [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (3/5 passes agreed)]
RDA-I3-01M — '(meta)data include references to other (meta)data' · RDA-I3-03M — 'metadata includes qualified references to other metadata' · FsF-I3-01M — F-UJI: 'Metadata includes links between the data and its related entities'
No license or terms document is named for the data; the article's CC BY license does not apply to the data.
RDA-R1.1-01M — 'Metadata includes information about the licence under which the data can be reu · RDA-R1.1-02M — 'Metadata refers to a standard reuse licence' · RDA-R1.1-03M — 'Metadata refers to a machine-understandable reuse licence'
“Medical records from patients were included in the study if the patient had an NSCLC with an EGFR mutation identified until the cut-off of February 2021”
A data cut-off date is given (February 2021). [majority verdict 'partial' (4/5 passes agreed)]
DataCite Metadata Schema 4.6 — the 'Version' property · RDA-R1.2-01M — provenance information (which version was used is provenance) · NSTC Desirable Characteristics of Data Repositories (2022) — 'Provenance', 'Retention Policy'
No code availability statement appears; the study's own code is not addressed.
NIH DMS Policy Element 2 (NOT-OD-21-014) — 'Related Tools, Software and/or Code' · FAIR4RS Principles v1.0 (Chue Hong et al., 2022; RDA/FORCE11/ReSA) — FAIR Principles for Resear · FORCE11 Software Citation Principles (Smith, Katz & Niemeyer, 2016, PeerJ CS 2:e86)
“This work was funded in part through the National Institutes of Health (NIH)/National Cancer Institute (NCI) grant R37 CA218707 (to D.B.C.) and LUNGevity EGFR Resisters/LUNGevity Research Award 1144389 (to S.S.K.).”
The paper gives an award/grant number (R37 CA218707) attached to a named funder.
DataCite Metadata Schema 4.6 — 'FundingReference' property (funderName, funderIdentifier, award · Crossref Funder Registry — canonical funder identifiers for funding metadata · RDA-F2-01M — rich metadata provided to allow discovery (funding is part of the descriptive reco
Advisory · not in the published score
The paper does not name the specific instruments, assays, platforms, kits, or software used to produce the data (only Stata for statistical analysis, which is not data production). [majority verdict 'no' (3/5 passes agreed)]
RDA-R1.2-01M — 'Metadata includes provenance information according to community- specific standa · FsF-R1.2-01M — F-UJI: 'Metadata includes provenance information about data creation or generati · W3C PROV-O (W3C Recommendation, 2013) — the entity/activity/agent model of provenance
“Table 1 Baseline Patient Characteristics of the Real-World BIDMC Cohort versus those of the FLAURA Trial.”
Variable definitions are provided in tables within the article, but no separate documentation file is named. [majority verdict 'partial' (4/5 passes agreed)]
RDA-R1-01M — '(Meta)data are richly described with a plurality of accurate and relevant attribu · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data' · NIH DMS Policy Element 3 (NOT-OD-21-014) — Standards (documentation and metadata to accompany t
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
0.434
From this paper's citation signal
Citation Network Contribution
0.323
From 11 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 17 citers.
National Institutes of Health (NIH)
Grant: R37 CA218707
National Institutes of Health (NIH)
Grant: 1144389
National Institutes of Health
Grant: 5R37CA218707-07
Unmet needs for specific subsets of EGFR mutated lung cancer
FWCI
4.69
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals